E. Hatashita

发表

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Kazuko Sakai, Kazuhiko Nakagawa, Kaoru Tanaka, 2012, Clinical Cancer Research.

Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition

M. Fukuoka, K. Nishio, K. Yanagihara, 2010, Molecular Cancer Therapeutics.

Abstract 5460: Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition

M. Fukuoka, K. Nishio, K. Yanagihara, 2010 .

Molecular Cancer Therapeutics Identification of cSrc as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to cSrc Inhibition

M. Fukuoka, K. Nishio, K. Yanagihara, 2010 .

Induction of MRP5 and SMRP mRNA by adriamycin exposure and its overexpression in human lung cancer cells resistant to adriamycin

M. Fukuoka, K. Nishio, E. Hatashita, 2001, International journal of cancer.

Amplification MET ( PF-02341066 ) in Gastric Cancer Positive for Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib

K. Nishio, K. Yanagihara, I. Okamoto, 2013 .

Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification

K. Nishio, K. Yanagihara, I. Okamoto, 2012, Molecular Cancer Therapeutics.

Preclinical Development Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib ( PF-02341066 ) in Gastric Cancer Positive for MET Ampli fi cation

K. Nishio, K. Yanagihara, I. Okamoto, 2012 .

Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs

M. Fukuoka, M. Sasamata, I. Okamoto, 2010, British Journal of Cancer.

Radiosensitizing Effect of YM155, a Novel Small-Molecule Survivin Suppressant, in Non–Small Cell Lung Cancer Cell Lines

M. Fukuoka, K. Ono, Minoru Suzuki, 2008, Clinical Cancer Research.

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells

P. Jänne, P. Janne, K. Azuma, 2012, British Journal of Cancer.

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib‐resistant non‐small cell lung cancer cells with acquired MET amplification

P. Jänne, M. Fukuoka, K. Nishio, 2010, Cancer science.

Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.

M. Fukuoka, I. Okamoto, K. Takezawa, 2010, Cancer research.

Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification

P. Jänne, M. Fukuoka, K. Nishio, 2009, Clinical Cancer Research.

TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation

Wataru Okamoto, Masahiro Fukuoka, Kazuhiko Nakagawa, 2010, Molecular Cancer Therapeutics.

Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase

Masahiro Fukuoka, Kenji Tamura, Junji Uchida, 2008, Molecular Cancer Therapeutics.

Overcoming Erlotinib Resistance in EGFR Mutation–Positive Non–Small Cell Lung Cancer Cells by Targeting Survivin

M. Ono, I. Okamoto, H. Yamaguchi, 2011, Molecular Cancer Therapeutics.

Inhibition of Insulin-Like Growth Factor 1 Receptor by CP-751,871 Radiosensitizes Non–Small Cell Lung Cancer Cells

M. Fukuoka, K. Ono, Minoru Suzuki, 2009, Clinical Cancer Research.

Cell Lung Cancer Small − Positive Non − Resistance to ALK Inhibitors in EML 4-ALK Activation of HER Family Signaling as a Mechanism of Acquired

Kaoru Tanaka, K. Nishio, I. Okamoto, 2013 .

Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status

M. Fukuoka, K. Ono, Minoru Suzuki, 2008, British Journal of Cancer.

Overcoming Erlotinib Resistance in EGFR Mutation-Positive Non-Small-Cell Lung Cancer Cells by Targeting Survivin

M. Ono, I. Okamoto, H. Yamaguchi, 2012 .

Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung Cancer

Kaoru Tanaka, K. Nishio, I. Okamoto, 2012, Clinical Cancer Research.

Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines with MET Amplification

P. Jänne, M. Fukuoka, K. Nishio, 2009, Clinical Cancer Research.